Contrary to the belief that HIV-infected injection drug users receive less benefit from highly active antiretroviral therapy, new research finds little difference in the survival rate between IDUs and non-IDUs after 4-5 years of receiving HAART, according to a study in the Aug. 6 issue of JAMA, a theme issue on HIV/AIDS.